Connectomica is a Chilean startup pharmaceutical company that focuses in the control of the inflammatory response using the human connexin hemichannel as a target. The company has developed a new drug to treat muscular dystrophy, a devastating and incurable disease, by selectively blocking this channel. Connectomica has shown that chronic use of this drug avoids muscular degeneration in animal models, offering a potential treatment for muscular dystrophy. The technology is also being applied in animal models of epilepsy with encouraging results.